导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.74% | 4012/4773 |
| 近一周 | -2.83% | 4669/5467 |
| 近一月 | -1.43% | 742/5421 |
| 近一季 | -10.03% | 3210/5238 |
| 近半年 | -16.14% | 4208/4931 |
| 近一年 | -1.78% | 2894/4400 |
| 近两年 | 41.94% | 1795/2954 |
| 近三年 | 1.96% | 1893/2253 |
| 成立以来 | 90.30% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.83% 2509/4961 |
-2.34% 3399/5312 |
- - |
- - |
| 2025 | 30.03% 1353/4813 |
0.71% 1785/3635 |
13.53% 60/4076 |
6.09% 3551/4524 |
7.21% 309/4813 |
| 2024 | -0.23% 2105/3463 |
-13.70% 2492/2808 |
0.42% 618/3014 |
13.08% 2249/3129 |
1.80% 1024/3463 |
| 2023 | -21.54% 1903/2656 |
-7.26% 2173/2280 |
-0.16% 366/2385 |
-9.79% 1897/2515 |
-6.06% 1615/2655 |
| 2022 | -26.43% 1399/2207 |
-25.70% 1786/1919 |
8.13% 386/2016 |
-5.28% 70/2113 |
-3.31% 1846/2208 |
| 2021 | 16.61% 264/1822 |
-20.21% 1210/1255 |
12.36% 337/1330 |
7.93% 169/1466 |
20.51% 27/1822 |
| 2020 | 95.20% 17/1250 |
0.60% 159/1028 |
15.44% 503/1067 |
31.94% 7/1164 |
27.39% 22/1184 |
| 2019 | - - |
- - |
- - |
- - |
2.98% 848/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证国防ETF VS. 长安沪深300非周期A(740101) |